Sanofi Ventures and Novartis Venture Fund have returned to back small molecule drug developer Expansion Therapeutics' series B round.
Expansion Therapeutics, a US-based developer of drugs for severe RNA-mediated diseases, completed an $80m series B round yesterday with investments from pharmaceutical firms Novartis and Sanofi.
Cormorant Asset Management led the round, which included Westlake Village BioPartners, Surveyor Capital, Logos Capital, RA Capital Management, 5AM Ventures and Kleiner Perkins, while Sanofi Ventures and Novartis Venture Fund represented Sanofi and Novartis respectively.
Founded in 2016, Expansion is focused on developing small molecule medicines for severe RNA-mediated diseases such as neurodegenerative and…
